No Result

View All Result

No products in the cart.

Home Tag relapsed and refractory multiple myeloma

Tag: relapsed and refractory multiple myeloma

$#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide$

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

byKathleen Lau

January 27, 2022

$#VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma$

#VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma

byKathleen Lau

September 23, 2021

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

byJessie Willisand1 others

September 8, 2021

1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% ...

$#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma$

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

byKathleen Lau

July 1, 2021

$#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma$

#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma

byKathleen Lau

March 19, 2021

Adding daratumumab increases progression free survival in multiple myeloma

Idecabtagene vicleucel showed a response in pre-treated multiple myeloma

bySze Wah Samuel Chanand1 others

February 26, 2021

1. Idecabtagene vicleucel treatment showed substantial antitumor activity in the majority of pre-treated patients with refractory and relapsed myeloma. 2. ...

#VisualAbstract Multiple Cereblon genetic alterations were associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

byKathleen Lau

February 11, 2021

$Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma$

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

byKathleen Lau

February 5, 2021

$#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX$

#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX

byKathleen Lau

December 10, 2020

#VisualAbstract Renal Toxicity Associated with Carfilzomib in Multiple Myeloma Patients

byKathleen Lau

December 3, 2020

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result